Drug
MT027 cells suspension
MT027 cells suspension is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(33%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Not yet recruiting2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
not_yet_recruiting267%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
not_yet_recruitingphase_1
Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors
NCT06742593
not_yet_recruitingphase_1
Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma
NCT06737146
recruitingphase_1
A Study of MT027 in Patients with Pleural Malignant Tumors
NCT06726564
Clinical Trials (3)
Showing 3 of 3 trials
NCT06742593Phase 1
Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors
NCT06737146Phase 1
Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma
NCT06726564Phase 1
A Study of MT027 in Patients with Pleural Malignant Tumors
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3